Nolvadex 20 mg

Nolvadex 20 mg contains tamoxifen citrate, a SERM. In medical practice it is used for breast cancer treatment and risk reduction in high-risk women. In non-medical bodybuilding contexts, it is commonly referenced for post-cycle therapy and managing gynecomastia during aromatizing cycles. Such use falls outside approved medical indications.

In medical practice, tamoxifen is typically taken once daily at 20 to 40 mg. In non-medical bodybuilding contexts, common reference points are 20 to 40 mg daily, with some protocols using a loading dose of 40 mg on the first day followed by 20 mg daily. Dosing should be individualized.

Tamoxifen is itself commonly used as a PCT agent, so it does not require a subsequent PCT. After a suppressive cycle, tamoxifen can help restore endogenous testosterone production by blocking estrogen's negative feedback. It may be used alongside other recovery agents like Clomid if desired.

Tamoxifen citrate is a SERM that competitively binds to estrogen receptors in target tissues, blocking estrogen's effects. In breast tissue, this can inhibit estrogen-dependent cancer cell growth. In bodybuilding contexts, this mechanism is used to block estrogen receptors in breast tissue and to stimulate endogenous testosterone production during PCT.

Following a single 20 mg oral dose, peak plasma concentrations occur approximately 5 hours after dosing. Steady-state concentrations are achieved in about 4 weeks with daily dosing. In PCT contexts, the effects on testosterone recovery are typically assessed over a 4-week protocol.

There is no single SERM that is universally best for PCT. Tamoxifen is one of the most commonly used, with a forum analysis showing 85% of users including it in their PCT protocols. Other options like Clomid are also commonly referenced, and the appropriate choice depends on individual response and circumstances.

Tamoxifen and Clomid are both SERMs used in PCT contexts, but they have different tissue selectivity profiles and pharmacokinetics. Tamoxifen has a longer half-life of about 5 to 7 days, while clomiphene has a shorter half-life. Some protocols combine both for a more comprehensive approach.

Tamoxifen and Arimidex work through different mechanisms. Tamoxifen is a SERM that blocks estrogen receptors, while Arimidex is an aromatase inhibitor that reduces estrogen production. They are not interchangeable and may be used for different purposes in cycle support.

In medical practice, 20 mg daily is the standard dose for many indications. In non-medical bodybuilding contexts, 20 mg daily is the most commonly referenced dose for PCT and gynecomastia management. The 20 mg strength of Nolvadex 20 mg aligns with these standard reference points.

Nolvadex 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. It is supplied in a 100-tablet package, giving 2,000 mg of total labeled tamoxifen citrate content.

Yes. Published laboratory reports include one dated April 18, 2025 measuring Nolvadex 20 mg at 21.05 mg/tablet (105.25% of label claim), and another dated August 26, 2024 measuring 21.36 mg/tablet (106.8% of label claim). The batch number for both reports was #TMXHD. Complete reports can be viewed in the Lab Reports tab.

Yes. Tamoxifen carries a boxed warning for thromboembolic events, including deep vein thrombosis and pulmonary embolism. In clinical trials, venous thromboembolic events occurred in approximately 5% of patients taking tamoxifen. The risk of blood clots may persist for up to 2 to 3 months after stopping tamoxifen.